What is GRAIL?
GRAIL operates at the vanguard of oncology diagnostics, leveraging advanced genomic sequencing to identify cancer at its earliest, most treatable stages. By analyzing circulating cell-free DNA in the bloodstream, the company's Galleri test represents a paradigm shift from reactive to proactive cancer management. Positioned as a high-growth healthcare technology entity, GRAIL integrates complex biological data with sophisticated machine learning to provide actionable insights for oncologists and healthcare providers. The company's market position is reinforced by a robust ecosystem of strategic partners, ranging from global pharmaceutical leaders to institutional investors, all aligned with the mission to reduce cancer-related mortality through early intervention.
How much funding has GRAIL raised?
GRAIL has raised a total of $2.3B across 7 funding rounds:
Series A
$100M
Series B
$900M
Series C
$300M
Unspecified
$125M
Series D
$390M
Stock/Share Issuance
$325M
Stock/Share Issuance
$110M
Series A (2016): $100M with participation from Biomatics Capital, ILLUMINA, Sutter Hill Ventures, Longwood Fund, Bill Gates, Bezos Expeditions, ARCH Venture Partners, and GV
Series B (2017): $900M led by JJDC, ARCH Venture Partners, Merck, McKesson, Bristol-Myers Squibb, Celgene, Amazon, Tencent HOldings Limited, and Varian Medical Systems
Series C (2018): $300M supported by Dimensions Capital, HuangPu River Capital, Hillhouse Capital Group, Ally Bridge Group, Sequoia Capital China, China Merchants Securities, WuXi NextCODE, Blue Pool Capital, CRF Investment, and ICBC International
Unspecified (2019): $125M, investors not publicly disclosed
Series D (2020): $390M backed by Public Sector Pension Investment Board, CPP Investments, and Illumina, Inc.
Stock/Share Issuance (2025): $325M with participation from Farallon, Deep Track Capital, Braidwell, and Him & Her
Stock/Share Issuance (2026): $110M led by Samsung C&T
Key Investors in GRAIL
Biomatics Capital
A venture firm focused on transformative data-enabled innovations at the intersection of healthcare and technology, supporting superior diagnostics and genomics.
ARCH Venture Partners
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists.
Merck
A global healthcare company delivering innovative solutions through prescription medicines, biologic therapies, and vaccines.
What's next for GRAIL?
With this major enterprise-level funding, GRAIL is well-positioned to transition into its next phase of commercial expansion and clinical validation. The strategic roadmap likely involves deepening the integration of its MCED technology into standard clinical workflows and broadening the accessibility of its diagnostic services. By leveraging the expertise of its diverse investor base, the company is expected to focus on long-term sustainability, potentially exploring new post-diagnostic applications and minimal residual disease detection. As GRAIL matures, the focus will shift toward achieving widespread reimbursement and establishing its platform as the gold standard in routine cancer screening, ultimately aiming to redefine the trajectory of global cancer care.
See full GRAIL company page
